Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) open the trading on Thursday, with a bit cautious approach as it glided -8.24% to $27.73, before settling in for the price of $30.22 at the close. Taking a more long-term approach, KNSA posted a 52-week range of $17.38-$30.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was 27.38%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 220.74%. This publicly-traded company’s shares outstanding now amounts to $42.16 million, simultaneously with a float of $40.46 million. The organization now has a market capitalization sitting at $2.02 billion. At the time of writing, stock’s 50-day Moving Average stood at $24.90, while the 200-day Moving Average is $22.98.
Kiniksa Pharmaceuticals International Plc (KNSA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Drug Manufacturers – Specialty & Generic industry. Kiniksa Pharmaceuticals International Plc’s current insider ownership accounts for 44.56%, in contrast to 55.50% institutional ownership. According to the most recent insider trade that took place on Jun 11 ’25, this organization’s Director sold 12,336 shares at the rate of 30.39, making the entire transaction reach 374,891 in total value, affecting insider ownership by 12,546. Preceding that transaction, on Jun 10 ’25, Company’s Director sold 8,212 for 30.36, making the whole transaction’s value amount to 249,316. This particular insider is now the holder of 12,546 in total.
Kiniksa Pharmaceuticals International Plc (KNSA) Earnings and Revenue Records
Kiniksa Pharmaceuticals International Plc’s EPS increase for this current 12-month fiscal period is 220.74% and is forecasted to reach 1.27 in the upcoming year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
Let’s observe the current performance indicators for Kiniksa Pharmaceuticals International Plc (KNSA). It’s Quick Ratio in the last reported quarter now stands at 3.43. The Stock has managed to achieve an average true range (ATR) of 1.16. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.21. Similarly, its price to free cash flow for trailing twelve months is now 46.27.
In the same vein, KNSA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.24, a figure that is expected to reach 0.19 in the next quarter, and analysts are predicting that it will be 1.27 at the market close of one year from today.
Technical Analysis of Kiniksa Pharmaceuticals International Plc (KNSA)
[Kiniksa Pharmaceuticals International Plc, KNSA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 60.46% While, its Average True Range was 1.20.
Raw Stochastic average of Kiniksa Pharmaceuticals International Plc (KNSA) in the period of the previous 100 days is set at 76.45%, which indicates a major rise in contrast to 40.68% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.81% that was lower than 52.11% volatility it exhibited in the past 100-days period.
